Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.…
Evaxion AS (EVAX) Q3 2026 Earnings Call Highlights: Strategic Pivot to Oncology and Extended ...
Evaxion announces strategy and business update and third quarter 2026 financial results
Evaxion (NASDAQ: EVAX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 46 employees.
The shares were at 2.250 USD on 20 November 2026, down 62.7% over 52 weeks. Its 52-week range is 2.030 USD to 6.920 USD: the price is 67.5% below the high and 10.8% above the low.
Its market capitalisation is 20.75M USD.
Evaxion reports return on equity of -45.2% and an operating margin of -116.0%.
It holds more cash than debt, a net cash position of 6.89M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.